Subclinical gut inflammation in ankylosing spondylitis

    Risultato della ricerca: Article

    30 Citazioni (Scopus)

    Abstract

    Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic innate lymphoid cells producing IL-22 and IL-17. Finally, a strong correlation between the presence of subclinical gut inflammation and the degree of spine inflammation have been also proved in AS. Summary Subclinical gut inflammation and innate immune responses in AS may be considered a possible consequence of microbial dysbiosis. Relationships between cause and effect remain, however, to be answered.
    Lingua originaleEnglish
    pagine (da-a)89-96
    Numero di pagine8
    RivistaCurrent Opinion in Rheumatology
    Volume28
    Stato di pubblicazionePublished - 2016

      Fingerprint

    All Science Journal Classification (ASJC) codes

    • Rheumatology

    Cita questo